# Millie S. Das, M.D.

# 3801 Miranda Avenue (111 Onc)

# Palo Alto, CA 94304

# mdas@stanford.edu

## Education

2000- 2004 M.D., University of Massachusetts Medical School, Worcester, MA

1996- 2000 B.S. in Biology, Minor in Literature

Massachusetts Institute of Technology, Cambridge, MA

## Postgraduate Training

2008- 2011 Fellowship in Medical Oncology/Hematology, Stanford University School of Medicine, Stanford, CA

March 2010 SPECTRUM Intensive Course in Clinical Research: Study Design and Performance Participant

* 1. Residency in Internal Medicine, Stanford University School of Medicine,

Stanford, CA

2004-2005 Internship in Internal Medicine, Stanford University School of Medicine,

Stanford, CA

**Academic Appointments:**

Jan 2013-present *Clinical Assistant Professor*, Stanford Cancer Institute, Stanford University School of Medicine, Stanford CA

Dec 2018-present *Member*, Stanford Cancer Institute, Stanford University School of Medicine,

Stanford, CA

Sept 2011- Dec 2012 *Clinical Instructor* (Affiliated), Stanford Cancer Institute, Stanford University

School of Medicine, Stanford CA

**Work Experience**

Nov 2016-present *Chief*, Oncology, VA Palo Alto Health Care System, Palo Alto, CA

Oct 2015-Oct 2016 *Acting Chief*, Oncology, VA Palo Alto Health Care System, Palo Alto, CA

2015-present *Associate Program Director*, Stanford Oncology Fellowship

Aug 2011-present *Chair*, VA Thoracic Tumor Board, VA Palo Alto Health Care System, Palo Alto, CA

Oct 2015-2018 *Chair*, VA Cancer Committee, VA Palo Alto Health Care System, Palo Alto, CA

Aug 2011-Sept 2015 *Staff Physician*, Oncology, VA Palo Alto Health Care System, Palo Alto, CA

* 1. *Hospitalist*, Providence Everett Medical Center, Everett Clinic, Everett WA

## Honors

2001 UMass Medical School Pathways Program Recipient

2004 John S. Efstathiou Award for compassion, caring, and understanding in the care of patients and their families

2010 Henzl-Gabor Travel Fellowship recipient

2010 Kirby Wilcox Postdoctoral Fellowship recipient

2010 Annual Stanford Oncology Retreat Poster Session winner

2010 National Lung Cancer Partnership Travel Grant recipient

## Board Certification

2007 American Board of Internal Medicine, Internal Medicine

2011 American Board of Internal Medicine, Medical Oncology

#### Professional Societies

American Society of Clinical Oncology (ASCO)

## International Association for the Study of Lung Cancer (IASLC)

**Teaching/Mentorship Positions**

2016-2017 Chair- Axis Medical Education certified educational activity in lung cancer

2017-present Faculty- Prime Oncology certified educational activity in lung cancer

2014-present Faculty- Clinical Care Options certified educational activity in lung cancer

2016-present Co-Director- VA Multidisciplinary CME Tumor Board

2013-present Planner- Stanford Cancer Education Series

2015-present ASCO Diversity Mentor

2015-present Stanford Med 313 medical student ambulatory clerkship mentor

2015-present Stanford SIMS undergraduate mentor

2013 Faculty editor of the Stanford Oncology Handbook

**Journal Reviewer**

## 2015 Ad hoc reviewer- *BMC Cancer*

2015 Ad hoc reviewer- *JAMA Oncology*

2016 Ad hoc reviewer- *Cancer Epidemiology, Biomarkers, and Prevention*

2017 Ad hoc reviewer- *Journal of Thoracic Disease*

2018 Ad hoc reviewer- *JCO Precision Oncology*

**Invited Lectures**

***National***

1. December 7, 2013. “Chemotherapy/Targeted Therapy- Locally Advanced NSCLC,” Best of World Conference on Lung Cancer, Intercontinental Hotel, San Francisco, CA.
2. February 6, 2014. “Cases in Non-small Cell Lung Cancer: A Workshop for Clinicians Working Within the Veterans Health Administration.” VA Loma Linda Health Care System. Loma Linda, CA.
3. May 15, 2015. “Current Management Strategies for Patients with Non-small Cell Lung Cancer in the Veterans Health Care Administration.” VA Albuquerque Health Care System. Albuquerque, NM.
4. October 3, 2015. “Chemotherapy/Targeted Therapy- Locally Advanced NSCLC,” Best of World Conference on Lung Cancer, Intercontinental Hotel, San Francisco, CA.
5. October 22, 2016. “Novel Therapies for Advanced NSCLC,” American Thoracic Society Conference 2016, Los Angeles Convention Center, Los Angeles, CA.
6. November 5th, 2016. “Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung,” JADPRO Live at APSHO 2016, Gaylord National Convention Center, National Harbor, MD.
7. March 23, 2017. “Paving the Way to Better Choices for Veterans with Lung Cancer,” Louis Stokes VA Medical Center, Cleveland, OH.
8. July 21, 2017. “Paving the Way to Better Choices for Veterans with Lung Cancer,” Wilkes Barre VA Medical Center, Wilkes Barre, PA.
9. December 7, 2017. “Paving the Way to Better Choices for Veterans with Lung Cancer,” Lebanon VA Medical Center, Lebanon, PA.
10. February 28, 2018. “Rallying the Troops: Optimizing the Use of Checkpoint Inhibitors in Non-Small Cell Lung Cancer,” VA Puget Sound, Seattle, WA.
11. May 4, 2018. “Optimal Sequencing of EGFR-Targeted Therapy in Advanced EGFR+ NSCLC: Applying New Data in Clinical Practice,” Teton Cancer Institute, Idaho Falls, ID.
12. May 19, 2018. “Stage III Lung Cancer: Do We Have Consensus?,” American Thoracic Society Conference 2018, San Diego, CA.

***Regional***

1. March 20-22, 2009. **“**Head and Neck Tumor Board,” Multidisciplinary Management of Cancers: A Case-based Approach, Silverado Resort, CA.
2. November 13, 2009**. “**Locally Advanced and Metastatic NSCLC Case Presentations,” NCCN Clinical Practice Guidelines in Oncology Symposium: NSCLC, Crowne Plaza Cabana, Palo Alto, CA.
3. August 10, 2017. “Expert Perspectives on Immunotherapy for NSCLC: Practical Guidance and Recommendations,” Pacifica Hospital of the Valley, Sun Valley, CA.
4. July 8, 2017. “Stage IV NSCLC Without Driver Alterations,” OncLive 2017 State of the Science Summit: Updates in Management of Adenocarcinoma of the Lung, San Jose Fairmont, San Jose, CA.
5. October 6, 2018. “Solid Tumors”, 2nd Annual Precision Medicine in Federal and Public Health Settings: Hematologic Malignancies and Solid Tumors, Beverly Hills Marriott, Beverly Hills, CA.
6. November 12, 2018. “Managing Progressive Non-Small Cell Lung Cancer: Second-Line Therapy and Beyond,” Prime Oncology, College Medical Center, Long Beach, CA.
7. November 29, 2018. “Expert Perspectives on Therapeutic Advances to Improve Treatment, Clinical Outcomes, and Quality of Life of Veterans with NSCLC,” Clinical Care Options, Las Vegas VA Medical Center, Las Vegas, NV.
8. February 11, 2019. “How I Treat: Lung Cancer in 2019,” Plenary session of Bay Area Lung Symposium, South San Francisco, CA.

***Stanford/VA***

1. March 6, 2012. **“**Targeting VEGF in Lung Cancer,” Cancer Education Seminar Series, Stanford Cancer Institute, Stanford, CA.
2. March 23, 2012. “Targeting VEGF in Lung Cancer,” Stanford Pulmonary Grand Rounds, Stanford University, Stanford, CA.
3. May 9, 2012. **“**Lung Cancer,” Women’s Health Forum, Li Ka Shing Center, Stanford University, Stanford, CA.
4. April 26-27, 2016. “Management of Stage III Lung Cancer: Medical Oncology Perspective,” Medical Education Program on Lung Cancer Management. Stanford University, Stanford, CA.
5. March 29, 2017. “Management of Stage III Lung Cancer: Medical Oncology Perspective,” Medical Education Program on Lung Cancer Management. Stanford University, Stanford, CA.
6. June 19, 2017. “Paving the Way to Better Choices for Veterans with Lung Cancer,” AXIS Medical Education, VA Palo Alto Health Care System, Palo Alto, CA.
7. September 14, 2017. “Treatment of Veterans With Advanced NSCLC: Guidance on Current Clinical Strategies,” Clinical Care Options Live Program Series, VA Palo Alto Health Care System, Palo Alto, CA.
8. November 29, 2017. “Treatment Options for Stage IV NSCLC: Focus on Immunotherapy and Those Without Driver Alterations,” Cancer Education Seminar. Stanford University, Stanford, CA.
9. March 22, 2017. “Rallying the Troops: Optimizing the Use of Checkpoint Inhibitors in Non-Small Cell Lung Cancer,” VA Palo Alto Health Care System, Palo Alto, CA
10. October 4, 2018. “Managing Progressive Non-Small Cell Lung Cancer: Second-Line Therapy and Beyond,” prIME Oncology, VA Palo Alto Health Care System, Palo Alto, CA.
11. February 11, 2019. “Expert Perspectives on Therapeutic Advances to Improve Clinical Outcomes of Veterans with NSCLC,” Clinical Care Options, VA Palo Alto Health Care System, Palo Alto, CA. *ly*

## Research Activities:

2018 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU). Funding: Abbvie, VA Site Principal Investigator

2018 Molecular Mechanisms of SCLC Initiation and Detection in Mice and Humans. Funding: U01 CA231851-01 (PI: Krasnow), Co-Investigator/VA site Principal Investigator

2018 Molecular Analysis of Small Cell Lung Cancer. Funding: R01 CA206540-01 (PI: Sage), Co-Investigator/VA Site Principal Investigator

2018 Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer, Sponsor: United Therapeutics, Site Principal Investigator.

2016-present The Baseline Study, Sponsor: Verily, Co-Investigator

2016-2018 A phase III Randomized, Multicenter, Safety and Efficacy Study to Evaluate Nab-paclitaxel as Maintenance Treatment after Induction with Nab-paclitaxel plus Carboplatin in Subjects with Squamous Non-small Cell Lung Cancer, Sponsor: Celgene, Site Principal Investigator

2011-2015 Bevacizumab or Pemetrexed Disodium Alone or in Combination After Induction Therapy in Treating Patients with Advanced Non-Small Cell Lung cancer, Sponsor: Eastern Cooperative Oncology Group, Site Co-Principal Investigator

2011-2015 BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (E6508), Sponsor: Eastern Cooperative Oncology Group, Site Co-Principal Investigator

2013-2016 Pemetrexed Disodium/Observation in Treating Patients with Malignant Mesothelioma Without Progressive Disease After First Line Chemotherapy, Sponsor: Alliance for Clinical Trials in Oncology, Site Principal Investigator

2013-2015 Cisplatin and Etoposide With or Without Veliparib in Treating Patients with Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer, Sponsor: National Cancer Institute, Site Principal Investigator

2010-2012 Phase I protocol for the combination of dovitinib and erlotinib in advanced non-small cell lung cancer, Sponsor: Novartis/Astellas, Co-Investigator

## Peer-Reviewed Original Research

1. **Das M**, Donington J, Murphy J, Kozak M, Eclov N, Whyte R, Hoang C, Zhou L, Le QT, Loo B, Wakelee H.  Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer (NSCLC).  *Clin Lung Cancer*. 2011 Jul; 12(5): 280-5.
2. **Das M\*,** Reiss J\*, Hsieh HB, Krivacic RT, Lazarus N, Bennis R, Ly J, Schwartz E, Zhou L, Nieva J, Wakelee H, Bruce R. A quantitative assay of ERCC1 expression in circulating tumor cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): a potential predictor of treatment response. *Lung Cancer.* 2012 Aug; 77(2): 421-6.
3. **Das M\***, Padda SK**\***, Frymoyer A, Riess J, Neal JW, Wakelee H. Dovitinib (TKI258) and Erlotinib in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC). *Lung Cancer*. 2015 Sept 89(3): 280-6.
4. Chaudhuri AA, Nabet A, Merriott DJ, Jin M, Chen EL, Chabon JJ, Newman AM, Stehr H, Say C, Carter JN, Walters S, Becker H, **Das M**, Padda SK, Loo BW, Wakelee HA, Neal JW, Alizadeh AA, Diehn M. Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. *Elsevier Science Inc*. 2018: E1-E2.
5. **Das M**, Padda SK, Frymoyer A, Molina J, Adjei A, Lensing J, Miles D, Sikic B, Wakelee H. XL647: A Safety, Tolerability, and Pharmacokinetic Analysis of Two Phase I Studies of Multitargeted Small Molecular Tyrosine Kinase Inhibitor XL647 with an Intermittent and Continuous Dosing Schedule in Patients with Advanced Solid Malignancies. *Cancer Chemotherapy Pharmacology* 2018 Sept 82(3):541-550.
6. Harris JP, Nwachukwu C, Qian Y, Pollom E, Loo BW, **Das M**, Diehn M. Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer. Lung Cancer 2018 Oct 124:76-85.

**Book Chapters**

1. **Das M**, Wakelee H. Stage IIIB and IV Disease NSCLC: Primary Therapy. Kernstine KH and Reckamp KL, (Eds). *Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management*. New York: Demos Medical Publishing, LLC, 2011: 183-195.
2. Ramchandran K, **Das M**, Wakelee H. Chapter 5: VEGFR-Inhibitors. Rajan A and Giaccone G (Eds). *Non-Small-Cell Lung Cancer* *(e-Book)*. 2012. Retrieved from futuremedicine.com.
3. **Das M**, Wakelee H. Chapter 34: Anti-angiogenic agents in Metastatic NSCLC. Roth JA, Hong WK, and Komaki RU (Eds). *Lung Cancer 4th Edition*. Hoboken, NJ: John Wiley and Sons, Inc., 2014: pp. 527-540
4. Myall, N and **Das, M**. Treatment of Stage III Lung Cancer. Clinics in Chest Medicine, Lung Cancer, Part II. Rivera MP (Ed). In process.

**Reviews**

1. **Roy MS**, Le Q, Donington J, Wakelee H. A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma. *Clin Lung Cancer.* 2006 Sep; 8(2): 146-8.
2. **Roy MS**, Le Q, Donington J, Wakelee H. Management of locally advanced non-small cell lung cancer from a surgical perspective. *Curr Treat Options Oncol.* 2007 Feb; 8(1): 1-14.
3. **Das M**, Abdelmaksoud M, Loo B, Kothary N. Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer. *Curr Treat Options Oncol*. 2010 Jun; 11(1-2): 24-35.
4. **Das M**, Wakelee H. Summary of the 10th annual ‘Targeted Therapies of the Treatment of Lung Cancer’ meeting in Santa Monica: Vascular disrupting agents. *J Thorac Oncol*. 2010 Nov; 5(12 Suppl 6): S482-3.
5. **Das M**, Wakelee H. Summary of the 11th annual ‘Targeted Therapies of the Treatment of Lung Cancer’ meeting in Santa Monica: Angiogenesis Inhibitors. *J Thorac Oncol*. 2011 Nov; 6(11 Suppl 4): S1801-2.
6. **Das M,** Wakelee H. Targeting VEGF in Lung Cancer. *Expert Opin Ther Targets*. 2012 April; 16(4): 395-406.
7. **Das, M**, Wakelee H. Summary of the 12th annual ‘Targeted Therapies of the Treatment of Lung Cancer’ meeting in Santa Monica: Angiogenesis Inhibitors. *J Thorac Oncol*. 2012 December 7(16 Suppl 5): S397-398.
8. **Das, M**, Wakelee, H. Anti-angiogenic agents in non-small cell lung cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study. *J Thorac Dis*. 2012 December 4(6): 558-561.
9. Riess JW, Nagpal S, **Das M**, Neal JW, Kim JW, Wakelee H. A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases: Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab*. J Thorac Oncol*. 2013 Feb; 8(2): e17-18.
10. Riess JW, Padda S, Bangs CD, **Das M**, Neal JW, Adrouny AC, Wakelee H. A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements*. Clin Lung Cancer*. 2013 Sept; 14(5):592-595.
11. **Das M**, Wakelee H. Angiogenesis and lung cancer: Ramucirumab prolongs survival in 2nd-line metastastic NSCLC. *Trans Lung Cancer*. 2014 Sept 10.
12. Chuang JC, Stehr H, Liang Y, **Das M**, Huang J, Diehn M, Wakelee HA, Neal JW. ERBB2 Mutated Metastatic Non-small Cell Lung Cancer: Response and Resistance to Targeted Therapies. *Journal of Thoracic Oncology*. 2017 Feb 3.
13. Harris JP, Nwachukwu C, Quian Y, Pollom E, Loo BW, **Das M**, Diehn M. Invasive Nodal Evaluation Prior to Stereotactic Ablative Radiation for Non-Small Cell Lung Cancer. *Lung Cancer*. 2018.

## Abstracts/Poster Presentations

1. **Roy M**, Le Q, Donington J, Wakelee H. A Multi-disciplinary Approach to Management in a Patient with Bilateral Superior Sulcus Non-Small-Cell Lung Carcinoma (Case Report). American College of Physicians Annual Poster Session, October 2005, Monterey, CA.
2. **Das M**, Hsieh HB, Krivacic R, Lazarus N, Bennis R, Ly J, Schwartz E, Zhou L, Bruce RH, Wakelee H. A quantitative assay of ERCC1 expression in circulating tumor cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): a potential predictor of treatment response. 10th Annual Targeted Therapies of the Treatment of Lung Cancer Poster Session, February 24-28, 2010, Santa Monica, CA.
3. **Das M**, Hsieh HB, Krivacic R, Lazarus N, Bennis R, Ly J, Schwartz E, Zhou L, Bruce RH, Wakelee H. A quantitative assay of ERCC1 expression in circulating tumor cells (CTCs) in Non-small Cell Lung Cancer (NSCLC): a potential predictor of treatment response (Updated results). 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, December 9-11, 2010, Chicago, IL.
4. **Das M**\*, Padda SK\*, Zhou L, Frymoyer A, Neal JW, Wakelee HA. Erlotinib and Dovitinib in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC). 15th World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
5. Nguyen KS, El-Masry M, Tham M, Howard L, Ventura R, Chwick K, **Das M**. Assessment of patients’ satisfaction of an innovative oncology telemedicine clinic. *J Clin Oncol* 2014; 32 (suppl; abstr e17506).

\*Contributed equally

**Non-peer Reviewed Publications**

1. Joshua Bauml, MD; Julie Beck, RN, MSN, MPH, APRN-BC; **Millie Das, MD**; Kelly Tammaro, PharmD, BCOP. Treatment and Management of Patients with Non-Small Cell Lung Cancer. *Federal Practitioner: Advances in Hematology and Oncology* Aug 2017. S26-S34.